| |
|
|
|
|
|
 |
| |
|
¿¤¸®°¡µåÁÖ30mg(·ùÇÁ·Î·¼¸°¾Æ¼¼Æ®»ê¿°) ELIGARD inj. 30mg
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
655601460[E01700221]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1°ü(2016.07.01)(ÇöÀç¾à°¡)
\399,243 ¿ø/1°ü(2015.12.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
½Ç¸°Áö A : ¹«»ö Åõ¸íÇÑ ½Ç¸°Áö¿¡ µç ¹«»ö ³»Áö ¿¶Àº Ȳ»öÀÇ Á¡¼º ¿ë¾×À¸·Î ¾µ ¶§ ½Ç¸°Áö B¿Í È¥ÇÕÇÏ¿© »ç¿ëÇÏ´Â ÁÖ»çÁ¦
½Ç¸°Áö B : ¹«»ö Åõ¸íÇÑ ½Ç¸°Áö¿¡ ¹é»ö - ȸ¹é»ö µ¿°á °ÇÁ¶¹°ÀÌ µç ¾µ ¶§ ½Ç¸°Áö A¿Í È¥ÇÕÇÏ¿© »ç¿ëÇÏ´Â ÁÖ»çÁ¦
½Ç¸°Áö A¿Í B È¥Çսà : ¹«»ö Åõ¸íÇÑ ½Ç¸°Áö¿¡ µç ¹àÀº Ȳ°¥»ö - Ȳ°¥»öÀÇ Åõ¸íÇÑ Á¡¼º ¿ë¾×ÀÌ ½Ç¸°Áö¿¡ ´ã°Ü ÀÖÀ¸¸ç ÷ºÎµÈ 1ȸ¿ë ÁÖ»çħÀ» ºÙ¿© »ç¿ëÇÏ´Â ÁÖ»çÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1°³ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 30¹Ð¸®±×·¥ |
1 °³ |
ÇÁ¸®Çʵå½Ã¸°Áö |
8806556014605 |
8806556014612 |
|
|
| ÁÖ¼ººÐÄÚµå |
182607BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
ÁøÇ༺ Àü¸³¼±¾ÏÀÇ ¿ÏÈ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
Ãßõ¿ë·®Àº ·ùÇÁ·Î·¼¸°¾Æ¼¼Æ®»ê¿°À¸·Î¼ 4°³¿ù¸¶´Ù 1ȸ 30mgÀ» ÇÇÇÏÁÖ»çÇÑ´Ù.
ÀÌ ¾à È¥ÇÕ ÈÄ 30ºÐ À̳»¿¡ Åõ¿©ÇÏ¿©¾ß ÇÑ´Ù.
´Ù¸¥ ¾à¹°°ú °°ÀÌ ÇÇÇÏÁÖ»çÇÒ ¶§ Á¤±âÀûÀ¸·Î ÁÖ»çºÎÀ§¸¦ º¯°æÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾àÀÇ ¼ººÐ, LHRH À¯»ç¾à¹°¿¡ ´ëÇØ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ¿©¼º ¹× ¼Ò¾Æ ȯÀÚ
3) È£¸£¸ó ºñÀÇÁ¸¼º Àü¸³¼±¾Ï ȯÀÚ
4) ¾çÂÊ °íȯ ÀýÁ¦¼úÀ» ¹ÞÀº ÈÄ, ÀÌ ¾à¿¡ ÀÇÇØ ´õ ÀÌ»ó Å×½ºÅ佺Å×·ÐÀÇ °¨¼Ò¸¦ ±â´ëÇÒ ¼ö ¾ø´Â ȯÀÚ
5) Áø´ÜµÈ ³úÇϼöü »ùÁ¾ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
1) ´ç´¢º´ ȯÀÚ
2) °íÇ÷¾Ð ȯÀÚ(°íÇ÷¾ÐÀÇ ¾ÇÈ À§ÇèÀÌ ÀÖ´Ù.)
3) ¿ì¿ïÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ(¿ì¿ïÁõ Àç¹ß ¶Ç´Â ¾ÇÈ À§ÇèÀÌ ÀÖ´Ù.)
|
| Ưº°È÷ ÁÖÀÇÇØ¾ßÇÒ ÀÌ»ó¹ÝÀÀ |
[Á¶È¸]
|
| ÀÌ»ó¹ÝÀÀ |
1) ³»ºÐºñ°è : ÀÌ ¾àÀº 90¸íÀÇ ÁøÇ༺ Àü¸³¼±¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î ÀÓ»óÀÌ ¼öÇàµÇ¾ú´Ù. ´Ù¸¥ LHRH À¯»ç¾à¹°°ú °°ÀÌ ÀÌ ¾à Åõ¿© Ãʱ⠸î ÁÖ¿¡´Â ÀϽÃÀûÀÎ Ç÷ûÅ×½ºÅ佺Å×·Ð ³óµµ Áõ°¡¸¦ ÀÏÀ¸Ä×À¸¹Ç·Î ôÃß ÀüÀÌ ¶Ç´Â ¿ä°üÆó»ö, Ç÷´¢°¡ Àִ ȯÀÚ¿¡¼ Ãʱ⠸î ÁÖ µ¿¾È Áõ»óÀÌ ¾Ç鵃 °¡´É¼º°ú °ü·ÃÀÌ ÀÖ´Ù. ÀÌ·¯ÇÑ °æ¿ì¿¡´Â ´ëÁõ¿ä¹ý µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇØ¾ß ÇÑ´Ù. ¶ÇÇÑ ´ç´¢º´ÀÌ ³ªÅ¸³ª°Å³ª Áõ»ó ¾ÇȰ¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ»óÀÌ °üÂûµÇ´Â °æ¿ì ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) ÁÖ»çºÎÀ§ : 90¸íÀÇ È¯ÀÚ´Â 8°³¿ù±îÁö 217ȸ Áֻ縦 ¹Þ¾Ò°í ÁÖ»çºÎÀ§¸¦ °üÂûÇÏ¿´´Ù. ÀϽÃÀûÀÎ ¿°¨/Âñ¸®´Â ÅëÁõÀÌ 35ȸ(20%) ÁÖ»çºÎÀ§¿¡¼ º¸°íµÇ¾ú°í ¸ðµç Áõ»ó(100%)Àº ¿Ï¸¸ÇÏ¿´´Ù. ÅëÁõÀº ÁÖ»çºÎÀ§ÀÇ 2.3%(ȯÀÚÀÇ 3.3%)¿¡¼ º¸°íµÇ¾ú°í °æµµÀÇ ÅëÁõÀ» ³ªÅ¸³Â´Ù. ºÎÁ¾ÀÌ 1.1%ÀÇ ÁÖ»çºÎÀ§(ȯÀÚÀÇ 2.2%)¿¡¼ º¸°íµÇ¾ú´Ù.
3) ±Ù°ñ°Ý°è : °íȯÀýÁ¦¼úÀ» ¹Þ°Å³ª LHRH À¯»ç¾à¹°À» Åõ¿© ¹ÞÀº ³²¼º¿¡¼ °ñ¹Ðµµ °¨¼Ò°¡ º¸°íµÇ¾ú´Ù. ÀÚÁÖ °üÀýÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) Àü½Å¹ÝÀÀ : Á¹À½, ¸Å¿ì ÀÚÁÖ ÇǷΰ¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ½ÉÇ÷°ü°è : ¸Å¿ì ÀÚÁÖ È«Á¶°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) »ý½Ä±â°è : À¯¹æÈ®´ë, ¹ß±âºÎÀü, À½°æ °¨¼Ò, ÀÚÁÖ °íȯÀ§Ãà, ¿©¼ºÇüÀ¯¹æ, °íȯÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) ½ÅÀå : ¿äÀý¹Ú, ¿ä½Ç±Ý, ÀÚÁÖ ¾ß´¢, ºó´¢°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) ¼Òȱâ°è : ÀÚÁÖ ±¸¿ªÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
9) ½Å°æ°è : ÀÚÁÖ Á¹¸²ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
10) ÇǺΠ: ÀÚÁÖ ³ÃÇÑ, ¾ß°£¹ßÇÑ, Å»¸ð°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
11) ±Ù°ñ°Ý°è : ±ÙÀ§Ãà, »çÁöÅë, ÀÚÁÖ ±ÙÀ°ÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
12) Á¤½Å½Å°æ°è : ºÒ¸éÁõ, ¿ì¿ïÁõ ÀÚÁÖ ¼º¿å°¨¼Ò°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ȯÀÚÀÇ »óŸ¦ ÃæºÐÈ÷ °üÂûÇØ¾ß ÇÑ´Ù.
13) ¿ì¿ïÁõ°ú ´Ù¸¥ Á¤½Å ÁúȯÀÇ º´·ÂÀ» °®°í Àִ ȯÀÚ Áß ¸¹Àº ȯÀڵ鿡°Ô¼ µå¹°°Ô ÀÚ»ì °ü³ä°ú ½ÃµµÀÇ º¸°í°¡ ÀÖ¾ú´Ù. ÀÌ ¾à Ä¡·áµ¿¾È ¿ì¿ïÁõÀÇ ¹ß»ý°ú »ó´ãÀ» ¹Þ¾Æ¾ß ÇÑ´Ù.
14) ½ÃÆÇ ÈÄ Á¶»ç¿¡¼ LHRH À¯»ç¾à¹°ÀÇ Åõ¿© ÈÄ µå¹°°Ô ³úÇϼöüÃâÇ÷ »ç·Ê°¡ º¸°íµÇ¾ú´Ù. ÀÌ °°Àº »ç·Ê Áß ´ëºÎºÐÀÇ °æ¿ì ³úÇϼöü »ùÁ¾ÀÌ Áø´ÜµÇ¾ú´Ù. ´ëºÎºÐÀÇ °æ¿ì LHRH À¯»ç¾à¹° Åõ¿© ÈÄ 2ÁÖ À̳»¿¡ ³ªÅ¸³µ°í ¸î¸î °æ¿ì´Â Åõ¿© ÈÄ ¸î ½Ã°£ À̳»¿¡ ³ªÅ¸³µ´Ù. ³úÇϼöüÃâÇ÷Àº µÎÅë, ±¸Åä, ½Ã·Âº¯È, ½Ã°¢±ÙÀ°¸¶ºñ, Á¤½Å»óÅ º¯È ¹× ÇãÇ÷ÀÌ ÇÔ²² ³ªÅ¸³´Ù. ÀÌ °æ¿ì Áöü ¾øÀÌ ÀÇ·á ½Ã¼úÀ» ÇØ¾ß ÇÑ´Ù. ÀÌ °°Àº ±Ù°Å¿¡ µû¶ó Áø´ÜµÈ ³úÇϼöü »ùÁ¾ ȯÀÚ¿¡´Â LHRH À¯»ç¾à¹°À» Åõ¿©Çؼ´Â ¾ÈµÈ´Ù. ¶ÇÇÑ, ½ÃÆÇ ÈÄ Á¶»ç¿¡¼ °£Áú¼º ÆóÁúȯÀÌ º¸°í µÇ¾ú´Ù.
|
| »óÈ£ÀÛ¿ë |
ÀÌ ¾àÀ¸·Î ¾àµ¿ÇÐÀ» ±Ù°Å·Î ÇÑ ¾à¹° »óÈ£ÀÛ¿ë ¿¬±¸´Â ½Ç½ÃµÇÁö ¾Ê¾Ò´Ù. ±×·¯³ª ·ùÇÁ·Î·¼¸°¾Æ¼¼Æ®»ê¿°Àº ÆéƼµå·Î¼ ½ÃÅäÅ©·Ò P-450 È¿¼Ò°¡ ¾Æ´Ñ ÆéƼµåºÐÇØÈ¿¼Ò¿¡ ÀÇÇØ ºÐÇØµÇ¸ç ´Ü¹é°áÇÕÀ²ÀÌ 46%¹Û¿¡ µÇÁö ¾ÊÀ¸¹Ç·Î ¾à¹°»óÈ£ÀÛ¿ëÀÌ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óµÇÁö ¾Ê´Â´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
655601460[E01700221]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1°ü(2016.07.01)(Ãֽžడ)
\399,243 ¿ø/1°ü(2015.12.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
½Ç¸°Áö A : ¹«»ö Åõ¸íÇÑ ½Ç¸°Áö¿¡ µç ¹«»ö ³»Áö ¿¶Àº Ȳ»öÀÇ Á¡¼º ¿ë¾×À¸·Î ¾µ ¶§ ½Ç¸°Áö B¿Í È¥ÇÕÇÏ¿© »ç¿ëÇÏ´Â ÁÖ»çÁ¦
½Ç¸°Áö B : ¹«»ö Åõ¸íÇÑ ½Ç¸°Áö¿¡ ¹é»ö - ȸ¹é»ö µ¿°á °ÇÁ¶¹°ÀÌ µç ¾µ ¶§ ½Ç¸°Áö A¿Í È¥ÇÕÇÏ¿© »ç¿ëÇÏ´Â ÁÖ»çÁ¦
½Ç¸°Áö A¿Í B È¥Çսà : ¹«»ö Åõ¸íÇÑ ½Ç¸°Áö¿¡ µç ¹àÀº Ȳ°¥»ö - Ȳ°¥»öÀÇ Åõ¸íÇÑ Á¡¼º ¿ë¾×ÀÌ ½Ç¸°Áö¿¡ ´ã°Ü ÀÖÀ¸¸ç ÷ºÎµÈ 1ȸ¿ë ÁÖ»çħÀ» ºÙ¿© »ç¿ëÇÏ´Â ÁÖ»çÁ¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
1°³ |
| º¸°ü¹æ¹ý |
¹ÐºÀ¿ë±â, ³ÃÀå(2-8¡É)º¸°ü |
Ư¼ö°ü¸®ÀǾàǰ ºÎ°¡Á¤º¸ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Brandname Á¤º¸ |
Leuprolide
Brand NamesEligard (Atrix Labs/QLT Inc)
Chemical IUPAC NameN-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin- 1-yl]-1-oxo-pentan-2-yl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl] -2-(4-hydroxyphenyl)ethyl]carbamoyl]-2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-yl) ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-pyrrolidine-2-carboxamide
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Xµî±Þ
(leuprolide; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
Á¹¸±¼ö ÀÖÀ¸´Ï ¿îÀüÀ̳ª À§ÇèÇÑ ±â°èÁ¶ÀÛÀº »ï°¡ÇØÁÖ¼¼¿ä |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| ÈÇб¸Á¶ ¹× ¹°¼º |
[LeuprolideÀÇ ÈÇб¸Á¶Á¤º¸]
 [LeuprolideÀÇ ¹°¼ºÁ¤º¸] CAS number/53714-56-0 ATC code/L02AE02 PubChem/441410 DrugBank/BTD00009 Formula/C59H84N16O12 Mol. mass/1209.4 g/mol Bioavailability/ ? Metabolism/ ? Excretion/Renal Pregnancy cat./
X Legal status/
℞ Prescription only Routes/Implant / Injection
|
| Mechanism of Action |
Leuprolide¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.
|
| Pharmacology |
Leuprolide¿¡ ´ëÇÑ Pharmacology Á¤º¸ Used in the palliative treatment of advanced prostate cancer. Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Leuprolide¿¡ ´ëÇÑ Description Á¤º¸ Synthetic 9 residue peptide analog of gonadotropin releasing hormone.
|
| Dosage Form |
Leuprolide¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid SubcutaneousSuspension, extended release IntramuscularSuspension, extended release Subcutaneous
|
| Drug Category |
Leuprolide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Estrogen AgentsAntineoplastic Agents
|
| Smiles String Canonical |
Leuprolide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1
|
| Smiles String Isomeric |
Leuprolide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](CCC\N=C(\N)N)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H]1CCC(=O)N1
|
| InChI Identifier |
Leuprolide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/f/h63,66-74H,60-61H2
|
| Chemical IUPAC Name |
Leuprolide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
|
| Drug-Induced Toxicity Related Proteins |
LEUPROLIDE ACETATE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Thyroid peroxidase Drug:leuprolide acetate Toxicity:thyroid disorder. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|